Released: Tuesday 11th March 2025

RoslinCT has entered into a strategic partnership with Gamida Cell to manufacture their FDA-Approved Cell Therapy Omisirge®, a commercial product for the treatment of hematologic malignancies commercialized in the US by Gamida Cell Inc, a subsidiary of Ayrmid Pharma Ltd.

This milestone further strengthens RoslinCT expertise and reinforces its ability to support its partners with high-quality, flexible, and scalable cell therapy CDMO solutions across clinical and commercial projects in both the US and UK.

For full details please click here.